EyePoint Pharmaceuticals

EYPT

Biotech

Health Care

Country

US

Industry

Health Care

Market Cap

Micro Cap

Num. Employees

144

IPO Date

Jan 27, 2005

Create Alert

EYPT

Country

US

Industry

Health Care

Biotech

Health Care

Create Alert

EyePoint Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that treat eye disorders. The company is headquartered in Watertown, Massachusetts and currently employs 144 full-time employees. The company went IPO on 2005-01-27. The firm is focused on the business of developing and commercializing ophthalmic products for the treatment of eye diseases. The firm's pipeline leverages its Durasert technology (Durasert) for sustained intraocular drug delivery, including delivery of EYP-1901, an investigational sustained delivery intravitreal treatment in Phase II clinical trials. The Company’s commercial product, YUTIQ, is a once-every-three-year treatment for chronic non-infectious uveitis affecting the posterior segment of the eye that utilizes a non-erodible formulation of Durasert. Its commercial product also includes DEXYCU, which is administered as a single dose directly into the surgical site at the end of ocular surgery and is a long-acting intraocular product for the treatment of post-operative inflammation. Its other products include ILUVIEN, Retisert, and Vitrasert.